Schedule 13G ownership disclosure

Monte Rosa Therapeutics Inc

Security class unavailable · CUSIP: 61225M102

Event date: 2022-01-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
4,858,627
Percent of class
10.4000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000080255-22-000973
Form type
SC 13G/A
Filer
Monte Rosa Therapeutics, Inc.
CIK
CIK 1826457
Filed
Feb 10, 2022
Reporting period
Jan 31, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub